Clinical trial
A Phase I/IB, First-Time-in-Human, Single Centre, Double-Blind, Randomized, Placebo-controlled, Dose Escalating Study of the Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of VB0004 Administered Orally to Healthy Volunteers; and to Patients With Mild to Moderate Hypertension With Low Cardiovascular Risk.
NCT04925050 is registered in ClinicalTrials.gov with Syneos Health as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I/IB, First-Time-in-Human, Single Centre, Double-Blind, Randomized, Placebo-controlled, Dose Escalating Study of the Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of VB0004 Administered Orally to Healthy Volunteers; and to Patients With Mild to Moderate Hypertension With Low Cardiovascular Risk.
- Lead sponsor
- Syneos Health
- Phase
- Phase 1
- Overall status
- Unknown status
- Start date
- June 17, 2021
- Completion date
- January 23, 2024
- Enrollment
- 88 (estimated)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.